Alex Denner

Published on February 21, 2015 at 5:27 pm by Insider Monkey Staff in

You can access the original SEC filing by clicking here.

Alex Denner

Sarissa Capital Management

Page 1 of 3 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Novelion Therapeutics Inc.

(Name of Issuer)

Common Stock, without par valuse

(Title of Class of Securities)

67001K103

(CUSIP Number)

Mark DiPaolo

General Counsel

Sarissa Capital Management LP

660 Steamboat Road

Greenwich, CT 06830

203-302-2330

With a copy to:

Russell Leaf

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019

212-728-8000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

August 1, 2017

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)

Page 2 of 3 – SEC Filing

Item 1. Security and Issuer.

This statement constitutes Amendment No. 2 to the Schedule 13D (this “Amendment No. 2”) relating to the Common Stock, without par value (the “Shares”), issued by Novelion Therapeutics, Inc. (the “Issuer”), and hereby amends the Schedule 13D filed with the Securities and Exchange Commission on December 5, 2016, as amended by Amendment No. 1 thereto filed with the Securities and Exchange Commission on June 30, 2017 (the “Initial Schedule 13D”), on behalf of the Reporting Persons (as defined in the Initial Schedule 13D), to furnish the additional information set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Initial Schedule 13D.

Item 4. Purpose of Transaction.

Item 4 of the Initial Schedule 13D is hereby amended by adding the following:

On August 1, 2017, the Board of Directors of the Issuer appointed Mark DiPaolo to serve as a director. Mr. DiPaolo is a partner and the General Counsel of Sarissa Capital.

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)

Page 3 of 3 – SEC Filing

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: August 4, 2017

SARISSA CAPITAL MANAGEMENT LP


By:	/s/ Mark DiPaolo
	Name: Mark DiPaolo
	Title: General Counsel


SARISSA CAPITAL DOMESTIC FUND LP
By: Sarissa Capital Fund GP LP, its general partner


By:	/s/ Mark DiPaolo
	Name: Mark DiPaolo
	Title: Authorized Person


SARISSA CAPITAL OFFSHORE MASTER FUND LP
By: Sarissa Capital Offshore Fund GP LLC, its general partner


By:	/s/ Mark DiPaolo
	Name: Mark DiPaolo
	Title: Authorized Person



/s/Alexander J. Denner
Alexander J. Denner

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)